The Fourth Annual Global Health Economics Colloquium:

The Economics of Non-Communicable Diseases

Friday, February 10, 2017 8:30 am-5:00 pm UCSF Mission Bay Genentech Hall

Policy makers worldwide need to optimize societal investments to improve the health of the populations they serve, while balancing competing societal priorities. The explosive increase in non-communicable diseases (NCDs) such as cardio-vascular disease, cancer, diabetes, and chronic respiratory conditions has led to an unprecedented pressure on scarce health care resources, even as the World Health Organization has established global targets to reduce premature mortality from NCDs by 25% by 2025.

Please join us for an exciting colloquium that brings together experts, policy makers, researchers, and trainees to discuss recent developments in the economics of NCDs and in cost-effectiveness analysis. Drawing upon NCD case studies from around the world, we will explore how high-quality economic evaluations can improve decision-making at regional and national levels. We will discuss new guidelines for cost-effectiveness analysis and the role of economics in reducing health inequality.

8:00 am Coffee and Registration

8:30 am Welcome and Opening Remarks by Organizers

**Dhruv Kazi**, Associate Professor of Medicine, UCSF **James G. Kahn**, Director, UCSF Global Health Economics

Consortium

**Douglas Owens**, Director, Center for Health Policy and Center for Primary Care and Outcomes Research, Stanford University **William Dow**, Kaiser Permanente Endowed Chair in Health Policy Management, UC Berkeley School of Public Health

8:45 am Economics of Non-Communicable Diseases (NCDs):

Case Studies from around the World

Moderator: Sergio Bautista, Mexico National Institute of

Public Health and UC Berkeley

Aging in Costa Rica, **Will Dow**, UC Berkeley Berkeley's Experience with the Soda Tax, **TBD** 

The Economics of Mental Health and Substance Abuse,

James G. Kahn, UCSF

10:15 am Keynote – Making the Economic Case for Investment

in NCD Prevention and Treatment

**Rachel Nugent**, Vice President for Chronic Disease, RTI Seattle, Editor, Disease Control Priorities Project (3rd Edition), and Member, *Lancet* Commission for NCDs and

Injuries of the Poorest Billion

11:30 am Optimal Study Design in Health Economics

Moderator: James G. Kahn, UCSF

Randomized Trials: Economic Incentives for Tobacco

Cessation, Justin White, UCSF

Instrumental Variables: Economic Status and Long-term

Health Outcomes, **Rita Hamad**, Stanford-UCSF Natural Experiment: The Association Between Free Trade

and Obesity, **Eran Bendavid**, Stanford University

Network Meta-analysis and Cost-Effectiveness in Oncology,

Jeroen Paul Jansen, Precision Economics

**12:45 pm Networking Lunch** (gourmet boxed lunches)

1:45 pm NCD Economic Evaluations in Action

A Pain in the Neck: Drug Costs in Rheumatology,

Jinoos Yazdany, UCSF

Should National Treatment Guidelines Incorporate Cost-Effectiveness Evaluations?, Mark Hlatky, Stanford

University

2:15 pm Keynote – Recommendations of the Second Panel on

**Cost-Effectiveness in Health and Medicine** 

**Gillian Sanders-Schmidler**, Co-Chair, Second Panel on Cost-Effectiveness in Health and Medicine; Past President, Society for Medical Decision Making; Associate Professor, Duke University; and Director, AHRQ-funded Evidence-

based Practice Center, Duke University

Discussant: **Douglas Owens**, Stanford University

3:45 pm Frontiers in Health Economics

Efficiency, Equity, and Ethics, Elliot Marseille, Health

Strategies International

Brave New World: Economics & Health under President #45,

Dhruv Kazi, UCSF

Integrated Care Delivery Models for NCDs, Neelam Sekhri

Feachem, UCSF

5:00 pm Reception





